DUBLIN--(BUSINESS WIRE)--The 'Ovarian Cancer Opportunity Assessment and Forecast' report has been added to ResearchAndMarkets.com's offering.

都柏林--（商业新闻短讯）--“卵巢癌机会评估和预测”报告已添加到ResearchAndMarkets.com的产品中。

Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being a rare cancer, ovarian cancer is a blockbuster market and is expected to grow from sales of $3.3 billion in 2022 to $4.1 billion in 2032 at a compound annual growth rate (CAGR) of 2.0%.

卵巢癌是全球最致命的妇科癌症之一。尽管是一种罕见的癌症，但卵巢癌是一个轰动一时的市场，预计销售额将从2022年的33亿美元增长到2032年的41亿美元，复合年增长率（CAGR）为2.0%。

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the publisher's World Markets Healthcare (WMH) and POLI Price Intelligence databases..

该报告包括对疾病流行病学的评估，以及针对市场和晚期管道治疗的7MM范围内的10年基于患者的预测（PBF），以及卵巢癌市场的发布日期评估。这些销售预测利用出版商的世界市场医疗保健（WMH）和POLI价格情报数据库中的药品销售和药品可用性数据。。

Ovarian cancer patients generally respond well to platinum-based chemotherapy and achieve complete remission in the initial setting. However, the risk of recurrence for patients with residual disease is high. Additionally, the rapid emergence of chemotherapy resistance is observed.

卵巢癌患者通常对铂类化疗反应良好，并在初始阶段达到完全缓解。然而，残留疾病患者的复发风险很高。此外，观察到化疗耐药性的迅速出现。

Currently, the standard treatment for platinum-resistant patients is sequential non-platinum treatment with either monotherapy or combination treatment with targeted therapy (bevacizumab) or cytotoxic agents (taxanes, gemcitabine, pegylated liposomal doxorubicin, or topotecan).There are several unmet needs in Ovarian Cancer that call for improved front-line treatment options and alternative options for platinum-resistant patients for extending overall survival in patients..

目前，铂类耐药患者的标准治疗方法是序贯非铂类治疗，单药治疗或联合靶向治疗（贝伐单抗）或细胞毒性药物（紫杉烷，吉西他滨，聚乙二醇化脂质体多柔比星或拓扑替康）。卵巢癌有几个未满足的需求，需要改进一线治疗方案和铂类耐药患者的替代方案，以延长患者的总体生存期。。

Major drivers of growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:

预测期内，700万卵巢癌市场增长的主要驱动因素包括：

The sales of ImmunoGen's Elahere represent the most impactful driver of growth for the ovarian cancer market. Elahere is anticipated to launch in the 5EU and Japan during the forecast period.

免疫原Elahere的销售代表了卵巢癌市场增长最具影响力的驱动力。预计Elahere将在预测期内在5EU和日本推出。

Combinations of PARP inhibitors, VEGF inhibitors, and ICIs are expected to launch in the 7MM during the forecast period.

预计在预测期间，PARP抑制剂，VEGF抑制剂和ICI的组合将在7MM内推出。

New drug launches for novel therapies will take considerable market share from generic chemotherapies.

新疗法的新药上市将从仿制药化学疗法中占据相当大的市场份额。

PARP inhibitors are established in the front-line maintenance setting with high treatment rates and are expected to retain their market share in the first-line setting.

PARP抑制剂建立在具有高治疗率的一线维护环境中，预计将在一线环境中保持其市场份额。

chemotherapies.

化疗

Major barriers to growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:

在预测期内，卵巢癌市场增长的主要障碍包括：

High costs and issues with reimbursement associated with both front-line treatments and prospective novel therapies may reduce uptake and off-label usage.

与一线治疗和前瞻性新疗法相关的高成本和报销问题可能会减少摄取和标签外使用。

Voluntary withdrawals and generic erosion upon the patent expiries of the PARP inhibitors will temper sales growth during the forecast period in the ovarian cancer market.

PARP抑制剂专利到期后的自愿退出和仿制药侵蚀将在预测期内抑制卵巢癌市场的销售增长。

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer.

本报告涵盖了7MM（美国，法国，德国，意大利，西班牙，英国和日本），包括对7MM市场和晚期管道治疗的疾病流行病学和10年基于患者的预测（PBF）的评估，以及卵巢癌市场的推出日期评估。

These sales forecasts leverage data on pharmaceutical sales and drug availability from the publisher's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

这些销售预测利用出版商的世界市场医疗保健（WMH）和POLI价格情报数据库中的药物销售和药物可用性数据。

Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being a rare cancer, ovarian cancer is a blockbuster market and is expected to grow from sales of $3.3 billion in 2022 to $4.1 billion in 2032 at a compound annual growth rate (CAGR) of 2.0%.

卵巢癌是全球最致命的妇科癌症之一。尽管是一种罕见的癌症，但卵巢癌是一个轰动一时的市场，预计销售额将从2022年的33亿美元增长到2032年的41亿美元，复合年增长率（CAGR）为2.0%。

Key Highlights

主要亮点

Report deliverables include a Pdf report and Excel-based forecast model

报告交付物包括Pdf报告和基于Excel的预测模型

Forecasts includes the 7MM

预测包括700万

Forecasts covers from 2022-2032

预测涵盖2022-2032年

The publisher valued the Ovarian Cancer market in the 7MM at $3.3 billion and expects the market to increase to $4.1 billion by 2032

该出版商估计，700万人中的卵巢癌市场价值为33亿美元，预计到2032年，该市场将增至41亿美元

ImmunoGen, AstraZeneca, Merck, and GSK are expected to take market-leading position in 2032

免疫原、阿斯利康、默克和葛兰素史克有望在2032年占据市场领先地位

A high level of unmet need will remain for most Ovarian Cancer patient populations during the forecast period

在预测期内，大多数卵巢癌患者的需求仍将保持较高水平

The Ovarian Cancer late-stage R&D pipeline is widely varied with several novel therapeutic classes

卵巢癌晚期研发渠道多种多样，有几种新的治疗类别

Scope

范围

Overview of Ovarian Cancer, including epidemiology, symptoms, diagnosis, and disease management.

卵巢癌概述，包括流行病学，症状，诊断和疾病管理。

Annualized Ovarian Cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.

2022年至2032年预测的卵巢癌治疗市场年收入，每位患者的治疗成本和治疗使用模式。

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Ovarian Cancer therapeutics market.

涵盖的关键主题包括战略竞争对手评估，市场表征，未满足的需求，临床试验绘图以及这些因素对卵巢癌治疗市场的影响。

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Ovarian Cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.

管道分析：综合数据评估正在开发的卵巢癌治疗新趋势和作用机制。介绍了第三阶段和第二阶段B开发中最有希望的候选人。

Analysis of the current and future market competition in the global Ovarian Cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

分析全球卵巢癌治疗市场的当前和未来市场竞争。对关键行业驱动因素、制约因素和挑战进行深入审查。每个趋势都是独立研究的，以提供对其影响的定性分析

Key Topics Covered:

涵盖的关键主题：

1. Preface

1、前言

1.1. Contents

一点一。目录

1.2. Related Reports

一点二。相关报告

1.3. Abbreviations

一点三。缩写

2. Executive Summary

2、执行摘要

3. Disease Overview

3、疾病概述

3.1. Overview of Ovarian Cancer

三点一。卵巢癌概述

3.2. Ovarian Cancer Strengths, Weaknesses, Opportunities, and Threats Analysis

三点二。卵巢癌的优势、劣势、机会和威胁分析

3.3. Classification of Ovarian Cancer

三点三。卵巢癌的分类

4. Epidemiology

4、流行病学

4.1. Diagnosed Incident Cases of Ovarian Cancer, Women, Ages ?18 Years, 2022-32

4.1条。确诊的卵巢癌事件，女性，年龄？18年，2022-32

4.2. Age-Specific Diagnosed Incident Cases of Ovarian Cancer, Women, 2022

四点二。2022年女性卵巢癌特定年龄诊断事件

4.3. Diagnosed Incident Cases of Epithelial Tumors by Histological Subtype, Women, Ages ?18 Years, 2022

四点三。按组织学亚型，女性，年龄诊断的上皮肿瘤事件？18年，2022年

4.4. Diagnosed Incident Cases of Ovarian Cancer by FIGO Stage, Women, Ages ?18 Years, 2022

四点四。按FIGO分期、女性、年龄诊断出的卵巢癌事件？18年，2022年

4.5. Five-Year Diagnosed Prevalent Cases, Women, Ages ?18 Years, 2022

四点五。五年诊断流行病例，女性，年龄？18年，2022年

4.6. Sources and Methodology for Diagnosed Incident Cases of Ovarian Cancer

四点六。卵巢癌确诊病例的来源和方法

4.7. Sources and Methodology

四点七。来源和方法

4.8. Sources and Methodology - Diagnosed Incidence of Ovarian Cancer

4.8条。来源和方法-卵巢癌的诊断发病率

4.9. Sources and Methodology - Five-Year Diagnosed Prevalent Cases of Ovarian Cancer

四点九。来源和方法-五年诊断的卵巢癌流行病例

4.10. Sources and Methodology - Diagnosed Incident Cases of Epithelial Tumors by Histological Subtype

4.10条。来源和方法-按组织学亚型诊断的上皮肿瘤事件病例

5. Current Treatment Options

5、目前的治疗方案

5.1. Ovarian Cancer Treatment Algorithm

5.1条。卵巢癌治疗算法

5.2. Treatment Paradigm - First-Line Therapy

五点二。治疗范例-一线治疗

5.3. Treatment Paradigm - Platinum-Status

五点三。治疗范例-白金状态

5.4. Current Treatment Options

五点四。当前治疗方案

5.5. Product Profile of VEGF Inhibitor (Avastin)

五点五。VEGF抑制剂（Avastin）的产品概况

5.6. Product Profiles of PARP Inhibitors (Lynparza, Rubraca, Zejula)

五点六。PARP抑制剂（Lynparza，Rubraca，Zejula）的产品概况

5.7. Product Profile of Kinase Inhibitor (Rozlytrek)

五点七。激酶抑制剂（Rozlytrek）的产品概况

5.8. Product Profile of Antibody-Drug Conjugate (Elahere)

五点八。抗体-药物偶联物（Elahere）的产品概况

6. Unmet Needs and Opportunities

未满足的需求和机会

7. R&D Strategies

7、研发策略

7.1. Trends in Ovarian Cancer Clinical Trial Design

7.1条。卵巢癌临床试验设计的趋势

7.2. Trends in Ovarian Cancer Deal-Making

七点二。卵巢癌交易的趋势

8. Pipeline Assessment

8、管道评估

8.1. Ovarian Cancer Pipeline Overview

8.1条。卵巢癌管道概述

8.2. Late-Stage Pipeline Agents for Ovarian Cancer

八点二。卵巢癌的晚期管道药物

8.3. Product Profile of Verastem Oncology's avutometinib + defactinib

8.3.Verastem Oncology的阿武替尼+德福替尼产品简介

8.4. Product Profile of Zentalis Pharmaceuticals's azenosertib

八点四。Zentalis Pharmaceuticals的azenosertib产品简介

8.5. Product Profile of Novartis's Femara (letrozole)

八点五。诺华Femara（来曲唑）产品简介

8.6. Product Profile of Alkermes's nemvaleukin

八点六。Alkermes的nemvaleukin产品简介

8.7. Product Profile of Corcept Therapeutics's relacorilant

八点七。Corcept Therapeutics相关产品简介

8.8. Product Profile of Genelux's Olvi-vec (olvimulogene nanivacirepvec)

8.8. Genelux的Olvi vec产品简介

8.9. Product Profile of AstraZeneca's cediranib maleate

八点九。阿斯利康马来酸西地拉尼的产品简介

8.10. Product Profile of Advenchen Laboratories's catequentinib

8.10条。Advenchen Laboratories的catequentinib产品简介

8.11. Product Profile of AstraZeneca's Imfinzi (durvalumab)

8.11.阿斯利康Imfinzi（durvalumab）的产品简介

8.12. Product Profile of Merck & Co's Keytruda (pembrolizumab)

8.12.默克公司Keytruda（pembrolizumab）产品简介

8.13. Product Profile of Roche's Tecentriq (atezolizumab)

8.13.罗氏Tecentriq（atezolizumab）的产品简介

8.14. Product Profile of GSK's Jemperli (dostarlimab)

8.14.葛兰素史克Jemperli（dostallimab）的产品简介

8.15. Product Profile of Bristol Myers Squibb / Ono Pharmaceuticals's Opdivo (nivolumab)

8.15.百时美施贵宝/Ono Pharmaceuticals的Opdivo（nivolumab）产品简介

8.16. Product Profile of OncoQuest's oregovomab

八点一六。OncoQuest的oregovomab产品简介

8.17. Product Profile of Eisai / Bristol Myers Squibb's farletuzumab ecteribulin

8.17.卫材/百时美施贵宝farletuzumab-ecteribulin产品简介

8.18. Product Profile of Mersana Therapeutics's upifitamab rilsodotin

八点一八。Mersana Therapeutics的upifitamab rilsodotin产品简介

8.19. Product Profile of Sutro Biopharma's luveltamab tazevibulin

8.19.Sutro Biopharma的luveltamab tazevibulin产品简介

9. Market Outlook

9、市场展望

9.1. Ovarian Cancer Clinical Trials by Trial Sponsors

9.1条。试验赞助商的卵巢癌临床试验

9.2. Ovarian Cancer Market Forecast

九点二。卵巢癌市场预测

9.3. Market Drivers and Barriers

九点三。市场驱动因素和障碍

10. Appendix

10、附录

For more information about this report visit https://www.researchandmarkets.com/r/w3s9hi

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/w3s9hi

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。